Kheiron Medical Technologies, London, UK.
MaMMa Egészségügyi Zrt., Budapest, Hungary.
Nat Med. 2023 Dec;29(12):3044-3049. doi: 10.1038/s41591-023-02625-9. Epub 2023 Nov 16.
Artificial intelligence (AI) has the potential to improve breast cancer screening; however, prospective evidence of the safe implementation of AI into real clinical practice is limited. A commercially available AI system was implemented as an additional reader to standard double reading to flag cases for further arbitration review among screened women. Performance was assessed prospectively in three phases: a single-center pilot rollout, a wider multicenter pilot rollout and a full live rollout. The results showed that, compared to double reading, implementing the AI-assisted additional-reader process could achieve 0.7-1.6 additional cancer detection per 1,000 cases, with 0.16-0.30% additional recalls, 0-0.23% unnecessary recalls and a 0.1-1.9% increase in positive predictive value (PPV) after 7-11% additional human reads of AI-flagged cases (equating to 4-6% additional overall reading workload). The majority of cancerous cases detected by the AI-assisted additional-reader process were invasive (83.3%) and small-sized (≤10 mm, 47.0%). This evaluation suggests that using AI as an additional reader can improve the early detection of breast cancer with relevant prognostic features, with minimal to no unnecessary recalls. Although the AI-assisted additional-reader workflow requires additional reads, the higher PPV suggests that it can increase screening effectiveness.
人工智能(AI)有可能改善乳腺癌筛查;然而,将 AI 安全地实际应用于临床实践的前瞻性证据有限。一种商业化的 AI 系统被用作标准双读的附加读取器,以标记筛查女性中进一步仲裁审查的病例。性能在三个阶段进行了前瞻性评估:单中心试点推出、更广泛的多中心试点推出和全面实时推出。结果表明,与双读相比,实施 AI 辅助附加读取器过程可以每 1000 例额外检测到 0.7-1.6 例癌症,额外召回率为 0.16-0.30%,不必要召回率为 0-0.23%,阳性预测值(PPV)增加 0.1-1.9%在对 AI 标记病例进行 7-11%的额外人工阅读后(相当于增加 4-6%的总体阅读工作量)。AI 辅助附加读取器过程检测到的大多数癌症病例为浸润性(83.3%)和小尺寸(≤10mm,47.0%)。这项评估表明,使用 AI 作为附加读取器可以提高具有相关预后特征的乳腺癌的早期检测,且召回率最低或无不必要召回。虽然 AI 辅助附加读取器工作流程需要额外的阅读,但更高的 PPV 表明它可以提高筛查效果。